Trial Profile

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BI 836858 (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Decitabine (Primary) ; Dubermatinib (Primary) ; Enasidenib (Primary) ; Entospletinib (Primary) ; Ficlatuzumab (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Lomonitinib (Primary) ; Pevonedistat (Primary) ; Revumenib (Primary) ; Samalizumab (Primary) ; SRA 515 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Biomarker; Therapeutic Use
Acronyms The Beat AML Trial

15 Jan 2026 According to Syndax Pharmaceuticals Media Release, first patient has received treatment in a new sub-study of its Beat AML Master Clinical Trial (Beat AML).
14 Jan 2026 According to AVEO oncology media release, the first patient has been dosed.
17 Dec 2025 The protocol has been amended for addition in number of arms.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com